VANCOUVER, British Columbia, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will report its third quarter 2024 financial results after market close on October 31, 2024. Following the announcement,... Read More

VANCOUVER, British Columbia, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat cancers and other diseases, today announced two presentations highlighting results from recent preclinical research for Zymeworks’ antibody-drug conjugate candidates... Read More

VANCOUVER, British Columbia, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today reported, as required by the Nasdaq Stock Market Rule 5635(c) (the “Nasdaq Rule”), an equity inducement award to Ms. Leone Patterson, Zymeworks’... Read More

VANCOUVER, British Columbia, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the following upcoming investor conferences: Wells Fargo Healthcare Conference: Zymeworks’ management will... Read More

VANCOUVER, British Columbia, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) (the “Company”), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that its Board of Directors has authorized a Share Repurchase Program under which the Company may repurchase up to $60.0... Read More

Reported $395.9 million in cash resources as of June 30, 2024, which when combined with certain anticipated regulatory milestone payments provides projected cash runway into 2H 2027 Priority Review of the Biologics License Application (BLA) granted for zanidatamab as second-line (2L) treatment for HER2-positive biliary tract cancers (BTC) in the United States with target action date of November 29, 2024 The European... Read More

VANCOUVER, British Columbia, July 30, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the following upcoming investor conferences: BTIG Virtual Biotechnology Conference: Zymeworks’ management... Read More

VANCOUVER, British Columbia, July 25, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced the appointment of Leone Patterson as Executive Vice President, and Chief Business and Financial Officer, effective September 1, 2024. “After... Read More

VANCOUVER, British Columbia, July 22, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the United States Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for ZW191, the Company’s... Read More

VANCOUVER, British Columbia, July 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will report its second quarter 2024 financial results after market close on August 1, 2024. Following the announcement,... Read More

VANCOUVER, British Columbia, June 17, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the United States Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for ZW171, a novel 2+1... Read More

Pursuant to the terms of the licensing agreement between Zymeworks and BeiGene, Zymeworks is entitled to receive an $8 million milestone payment from BeiGene and remains eligible to receive up to $164 million based on additional milestones plus royalties on product sales A Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for zanidatamab as a treatment for previously-treated, unresectable,... Read More

VANCOUVER, British Columbia, May 28, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the following upcoming investor conferences: Jefferies Global Healthcare Conference: Zymeworks’ management... Read More

Reported $420.5 million in cash resources as of March 31, 2024, which when combined with certain anticipated regulatory milestone payments provides projected cash runway into 2H 2027 Completion of rolling biologics license application (BLA) filing with the U.S. Food and Drug Administration (FDA) for zanidatamab as second-line treatment for biliary tract cancers (BTC) in the United States (U.S.) by our partner, Jazz... Read More

VANCOUVER, British Columbia, April 30, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the following upcoming investor conferences: Bank of America Securities Health Care Conference:... Read More

VANCOUVER, British Columbia, April 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will report its first quarter 2024 financial results after market close on May 2, 2024. Following the announcement,... Read More

VANCOUVER, British Columbia, April 08, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced five presentations including new data from its preclinical development-stage programs at the 2024 American Association for Cancer Research... Read More

VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced the appointment of Dr. Neil Gallagher to its board of directors effective April 2, 2024. “Dr. Gallagher is the sixth director to join our... Read More

VANCOUVER, British Columbia, March 27, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the following upcoming investor conferences: 23 rd Annual Needham Virtual Healthcare Conference:... Read More

Reported $456.3 million in cash resources as of December 31, 2023, which when combined with certain anticipated regulatory milestone payments provides projected cash runway into 2H 2027 Initiation of rolling biologics license application (BLA) filing with the FDA for zanidatamab as second-line treatment for biliary tract cancers (BTC) in the United States (US) with anticipated completion of regulatory submission in 1H 2024... Read More

Five abstracts accepted for poster presentation highlight company’s differentiated antibody-drug conjugate and multispecific antibody clinical product candidates Strong preclinical activity across multiple FRα-expressing indications for ZW191, a FRα-targeting antibody-drug conjugate Next generation trispecific T cell engager platforms with integrated CD28 costimulation demonstrate durable anti-tumor activity VANCOUVER,... Read More

VANCOUVER, British Columbia, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the following upcoming investor conferences: TD Cowen 44 th Annual Health Care Conference: Zymeworks’... Read More

VANCOUVER, British Columbia, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will report its fourth quarter 2023 financial results after market close on March 6, 2024. Following the announcement,... Read More

VANCOUVER, British Columbia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced the appointment of Dr. Alessandra Cesano to its board of directors effective February 8, 2024. Dr. Cesano succeeds Dr. Kenneth Hillan, who... Read More

VANCOUVER, British Columbia, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the following upcoming investor conferences: Guggenheim Healthcare Talks 6 th Annual Biotechnology... Read More

Company well-positioned for further progress and broadening of R&D pipeline Cash resources of approximately $455 million as of December 31, 2023 (unaudited) Expected cash runway, including proceeds from recent private placement, into 2H 2027 Top-line data readout from the Phase 3 trial evaluating zanidatamab in HER2-positive gastroesophageal adenocarcinoma (GEA), HERIZON-GEA-01, expected in 2024 Expected regulatory reviews... Read More

Dr. Jeffrey Smith named Executive Vice President and Chief Medical Officer Dr. John Fann promoted to Senior VP, Process Sciences Seven new Vice Presidents appointed, underscoring commitment to leadership development VANCOUVER, British Columbia, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to... Read More

VANCOUVER, British Columbia, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biopharmaceutical company developing novel, multifunctional biotherapeutics, today announced that it had entered into a securities purchase agreement with funds affiliated with EcoR1 Capital, LLC (“EcoR1 Capital”), for the sale of an aggregate of 5,086,521 pre-funded warrants to purchase 5,086,521 shares of common... Read More

VANCOUVER, British Columbia, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced it is expected to be added to the Nasdaq Biotechnology Index (Nasdaq: NBI) (the “NBI”). Zymeworks’ addition to the NBI will become effective prior to the market open on Monday, December 18, 2023. The NBI is designed to track the... Read More

VANCOUVER, British Columbia, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in an upcoming investor conference: 42 nd Annual J.P. Morgan Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings on January 8-11, 2024 and a corporate... Read More

Net loss for the first nine months of 2023 decreased by 44% as compared to the same period in 2022 Cash resources of $390.2 million as of September 30, 2023 expected to fund planned operations through at least the end of 2026, and potentially beyond Updated clinical results from Phase 1b/2 study of zanidatamab plus chemotherapy and tislelizumab as first-line therapy for patients with advanced HER2-positive gastroesophageal... Read More

VANCOUVER, British Columbia, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences: Jefferies London Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings and a fireside chat on November 14 th at... Read More

VANCOUVER, British Columbia, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will report its third quarter 2023 financial results after market close on November 7, 2023. Following the announcement, management will host a conference call and webcast to discuss financial results and provide... Read More

Net loss for the first six months of 2023 decreased by 45% as compared to the same period in 2022 Cash resources of $431.4 million as of June 30, 2023 expected to fund planned operations through at least the end of 2026, and potentially beyond Presented full clinical results from Phase 2b study of zanidatamab monotherapy in previously treated HER2-amplified biliary tract cancers (BTC) at the Annual Meeting of American... Read More

VANCOUVER, British Columbia, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences: Citi's 2023 18 th Annual BioPharma Conference: Zymeworks’ management will participate in one-on-one meetings and a co-panel discussion on September... Read More

VANCOUVER, British Columbia, July 19, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will report its second quarter 2023 financial results after market close on August 10, 2023. Following the announcement, management will host a conference call and webcast to discuss financial results and provide... Read More

VANCOUVER, British Columbia, July 03, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conference: BTIG Virtual Biotechnology Conference 2023: Zymeworks’ management will participate in one-on-one meetings on Aug 7– 8 All presentations and webcasts... Read More

VANCOUVER, British Columbia, June 29, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced the appointment of Mr. Carlos E. Campoy to its board of directors effective as of June 30, 2023. Mr. Campoy brings extensive strategic and financial leadership experience in the pharmaceutical and biotechnology sectors to the... Read More

VANCOUVER, British Columbia, June 26, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that it is set to join both the Russell 3000®, Russell 2000 ® , and the Russell Microcap® Indexes at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the U.S. market opens on June 26, 2023. The... Read More

VANCOUVER, British Columbia, June 01, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences: Jefferies Global Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings and present on June 8 at 1:00 pm Eastern... Read More

VANCOUVER, British Columbia, May 18, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced the departure of Neil Klompas, President and Chief Operating Officer. Mr. Klompas joined Zymeworks in 2007 as Chief Financial Officer and served in multiple capacities until being named Chief Operating Officer and President in... Read More

Confirmed prior guidance on 2023 operating cash burn of between $90 and $120 million and cash runway through at least 2026, and potentially beyond Net quarterly loss decreased by 66% to $24.4 million as compared to first quarter in 2022 Presented 11 posters at the American Association for Cancer Research (AACR) showcasing Zymeworks' focused preclinical antibody-drug conjugate (ADC) and multispecific antibody therapeutics... Read More

VANCOUVER, British Columbia, May 01, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences: Bank of America Global Healthcare Conference. Zymeworks’ management will participate in one-on-one meetings and present on May 11 at 8:55 am Pacific... Read More

ZW191 demonstrates strong responses in FRα-low expressing patient-derived xenograft (PDX) models with favorable pharmacokinetic and safety profiles ZW171 induced potent preferential killing of cancer cells and potential to mitigate risk of on-target off-tumor toxicity, peripheral T cell activation, and cytokine-release syndrome ZW251 exhibits desired target-mediated activity in vitro and robust anti-tumor activity in PDX... Read More

VANCOUVER, British Columbia / Apr 17, 2023 / Business Wire / Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will report its first quarter 2023 financial results after market close on May 8, 2023. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a... Read More

VANCOUVER, British Columbia / Apr 10, 2023 / Business Wire / Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced the appointment of Derek J. Miller to its board of directors effective April 10, 2023. Mr. Miller brings extensive commercial, corporate and business development, and senior leadership experience in oncology to the Zymeworks board... Read More

VANCOUVER, British Columbia / Apr 03, 2023 / Business Wire / Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences: 2023 Bloom Burton & Co. Healthcare Investor Conference. Zymeworks’ management will participate in one-on-one meetings and present on April 25 th in... Read More

VANCOUVER, British Columbia / Mar 14, 2023 / Business Wire / Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced the acceptance of eleven abstracts for poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting taking place at the Orange County Convention Center in Orlando, FL from April 14 – 19, 2023.... Read More

VANCOUVER, British Columbia / Mar 07, 2023 / Business Wire / Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel multifunctional biotherapeutics, today reported financial results for the fourth quarter and year ended December 31, 2022 and provided a summary of recent business highlights. “As I reflect on the past year as Zymeworks' new Chair and CEO, we made significant progress across all... Read More

VANCOUVER, British Columbia / Feb 21, 2023 / Business Wire / Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will report its fourth quarter and full year 2022 financial results after market close on March 7 th , 2023. Following the announcement, management will host a conference call and webcast to discuss financial... Read More

VANCOUVER, British Columbia / Jan 25, 2023 / Business Wire / Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences: Guggenheim Oncology Conference 2023. Zymeworks’ management will participate in one-on-one meetings on February 8 th – 9 th and a fireside chat on... Read More

Provides updated key priorities and focus on enterprise value framework Closing of Jazz Pharmaceuticals (Jazz) collaboration in fourth quarter completes financial transformation initiatives originally planned for 2022 Announces additional financial guidance on expected cash runway; provides unaudited cash and cash resources balance as of December 31, 2022 Announces recommended Phase 2 dose (RP2D) for zanidatamab zovodotin... Read More

Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in an upcoming investor conference: JP Morgan Healthcare Conference . Zymeworks’ management will participate in one-on-one meetings on January 12 th and a corporate presentation on January 12 th at 10:30 am Pacific Time (PT). All presentations and webcasts... Read More

Follows positive top-line clinical data readout from HERIZON-BTC-01 pivotal trial in biliary tract cancers DUBLIN and VANCOUVER, BC , Dec. 21, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Zymeworks Inc. (Nasdaq: ZYME) today announced that Jazz has exercised its option to continue with its exclusive development and commercialization rights to Zymeworks' zanidatamab in key markets, including the U.S.,... Read More

Zanidatamab as monotherapy produced a confirmed objective response rate (cORR) of 41.3% and median duration of response of 12.9 months in patients with previously treated HER2-amplified and expressing biliary tract cancers (BTC) Pending receipt of regulatory approvals, zanidatamab has the potential to be the first HER2-targeted therapy for patients with BTC Zymeworks to host conference call today at 8:00 am Eastern Time (ET)... Read More

VANCOUVER, British Columbia--( BUSINESS WIRE )-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the upcoming presentation of mature Phase 2 data evaluating zanidatamab in combination with chemotherapy as first-line treatment for HER2-positive gastroesophageal adenocarcinoma (GEA) at the ASCO Gastrointestinal Cancers Symposium, taking place... Read More

VANCOUVER, British Columbia--( BUSINESS WIRE )- -Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today presented new clinical data for zanidatamab, the company’s investigational HER2-targeted bispecific antibody, in combination with palbociclib, a CDK4/6 inhibitor, and fulvestrant, a selective estrogen receptor degrader, in patients with heavily pretreated... Read More